Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2013-05-29 | 4,6,4’-trymethylangelicin | Rare Partners srl Impresa Sociale (Italy) | cystic fibrosis | |
2013-06-19 | adenovirus associated viral vector serotype 5 containing the human pde6Beta gene | CHU Nantes (France) | retinitis pigmentosa |
Granting of the orphan status in the EU |
2013-05-29 | copper meso-5,15-bis[3-[(1,2-dicarba-closo-dodecaboranyl)methoxy]phenyl]-meso- 12,20-dinitroporphyrin | MorEx Development Partners LLP (UK) | squamous cell carcinoma of the head and neck in patients undergoing radiotherapy |
|
2015-05-22 | expanded human allogeneic neural retinal progenitor cells extracted from neural retina | Reneuron (UK) | retinitis pigmentosa |
Granting of a Fast Track status |
2013-07-24 | genetically modified serotype 5/3 adenovirus coding for granulocyte-macrophage colony-stimulating factor (G-CSF) | Oncos Therapeutic (Finland) | soft tissue sarcoma |
Granting of the orphan status in the US |
2013-05-29 | immortalised human C3A hepatoblastoma cells | Vital Therapies Limited (USA) | acute liver failure |
Granting of a patent |
2015-01-26 | recombinant human alpha-N-acetylglucosaminidase | Synageva BioPharma (USA) | mucopolysaccharidosis type IIIB (Sanfilippo B syndrome) |
Granting of a Fast Track status |
2013-05-29 | sodium chlorite | Shore Limited | amyotrophic lateral sclerosis | |
2013-05-29 | synthetic double-stranded siRNA oligonucleotide directed against the keratin 6a N171K mutation | Alan Irvine | pachyonychia congenita | |
2013-06-19 | unoprostone isopropyl | Sucampo Pharma Europe (UK) | retinitis pigmentosa |
Granting of the orphan status in the EU |
2013-05-31 | real-time PCR test for the simultaneous detection of both BRAF V600E and V600K mutations | bioMérieux (France) | metastatic melanoma | |
2013-06-02 | lipegfilgrastim | Teva Pharmaceutical Industries (Israel) |
|
Product launch |
2013-06-02 | somatropin | Biopartners (Switzerland) | ong-term treatment of growth failure in children and adolescents due to insufficient secretion of endogenous growth hormone replacement therapy of endogenous growth hormone in adults with growth hormone deficiency (GHD) |
|
2015-07-31 | human coagulation factor VIII and human Von Willebrand factor | CSL Behring (Germany) |
|
Granting of a Market Authorisation in the EU |
2016-11-21 | combination of insulin degludec (Tresiba®) and liraglutide (Victoza®) | Novo Nordisk (Denmark) | type 2 diabetes |
Granting of a Market Authorisation in the US |
2013-06-05 | neostigmine methylsulfate | Flamel Technologies (France) | reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery | |
2013-06-07 | ranibizumab | Novartis (Switzerland) | visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV) |
Granting of a Market Authorisation in the EU |
2013-06-10 | four-strain influenza vaccine | Sanofi Pasteur (France) | prevention of influenza |
Granting of a Market Authorisation in the US |
2013-06-13 | allergy vaccine | Anergis (Switzerland) | dust mite allergy |
Granting of a patent |
2013-06-18 | denosumab | Amgen (USA) | giant cell tumor of the bone | Positive opinion for the granting of a Market Authorisation in the EU |
© 2024 Biopharmanalyses - Powered by Samacom+